NEW YORK, Sept. 14 (GenomeWeb News) - Invitrogen will use its ProtoArray protein microarrays to develop diagnostic and screening tools for cancer under a collaboration with the Fred Hutchinson Cancer Research Center, the partners announced yesterday.
Invitrogen said it would apply its protein and antibody collections to the collaboration with researchers in the lab of Sam Hanash. The firm will have rights under the multi-year program to license technologies that result from the collaboration. Further terms of the alliance were not disclosed.
This is Invitrogen's second partnership within the past year aimed at discovering cancer biomarkers. The first, signed in December 2004, is with the Mayo Clinic. Under that collaboration, Invitrogen provides financial and research support for multiple biomarker discovery programs at Mayo, and has an option to license and develop resulting technology on an exclusive and non-exclusive basis.